Paper Details

  1. Home
  2. Paper Details

Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.

Author: AnagnostisPanagiotis, CeausuIuliana, DepypereHerman, GoulisDimitrios G, LambrinoudakiIrene, MintzioriGesthimani, MueckAlfred, PaschouStavroula A, Pérez-LópezFaustino R, ReesMargaret, SenturkLevent M, SimonciniTommaso, StevensonJohn C, StutePetra, TrémollieresFlorence A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Bisphosphonates and denosumab are commonly used to treat osteoporosis in women after menopause. While they are effective at preventing fractures, the optimal treatment duration is unclear. Side effects like jawbone death (ONJ) and unusual thighbone fractures (AFF) have raised questions about stopping these medications ("drug holiday") after a period of time.
Paper Details　
Original Abstract of the Article :
Bisphosphonates and denosumab are used extensively in the treatment of postmenopausal osteoporosis. Despite their proven efficacy in the reduction of vertebral and non-vertebral fractures, their optimal duration of use has not been determined. The occurrence of adverse effects, such as osteonecrosis...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.maturitas.2017.04.008

データ提供：米国国立医学図書館（NLM）

Drug Holidays from Bisphosphonates and Denosumab

Osteoporosis, a condition that weakens bones, can be likened to a desert landscape with crumbling structures. This research explores the potential benefits and risks of 'drug holidays,' periods of discontinuation, from bisphosphonates and denosumab, medications commonly used to treat osteoporosis. The authors present a position statement outlining the current understanding of drug holidays in this context.

Navigating the Desert of Osteoporosis Treatment

The researchers acknowledge the effectiveness of bisphosphonates and denosumab in reducing fracture risk. However, they also highlight the potential for adverse effects, including osteonecrosis of the jaw and atypical femoral fractures, leading to concerns about the optimal duration of treatment. This research provides a framework for considering drug holidays as a potential strategy for managing osteoporosis, weighing the benefits against the potential risks. It's like carefully evaluating the different paths through the desert of osteoporosis treatment, seeking the safest and most effective route for each individual.

Finding Balance: Oasis in the Desert of Osteoporosis

This research emphasizes the importance of individualized management for osteoporosis. By carefully considering the benefits and risks of drug holidays, clinicians can create a personalized treatment plan that balances fracture prevention with the potential for adverse effects. It's like finding a path through the desert of osteoporosis treatment that balances the need for stability with the desire for flexibility.

Dr.Camel's Conclusion

This position statement provides valuable insights into the complex landscape of drug holidays in osteoporosis management. By carefully considering the potential benefits and risks, clinicians can navigate the desert of osteoporosis treatment, tailoring treatment strategies to individual needs and ensuring the best possible outcomes for their patients.

Date :
  1. Date Completed 2017-11-08
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

28539165

DOI: Digital Object Identifier

10.1016/j.maturitas.2017.04.008

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.